- Home
- BMEA vs JMM Comparison
BMEA vs JMM Comparison
Compare BMEA & JMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- JMM
- Stock Information
- Founded
- BMEA 2017
- JMM 1988
- Country
- BMEA United States
- JMM United States
- Employees
- BMEA N/A
- JMM N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- JMM Trusts Except Educational Religious and Charitable
- Sector
- BMEA Health Care
- JMM Finance
- Exchange
- BMEA Nasdaq
- JMM Nasdaq
- Market Cap
- BMEA 65.8M
- JMM 59.9M
- IPO Year
- BMEA 2021
- JMM N/A
- Fundamental
- Price
- BMEA $1.93
- JMM $6.43
- Analyst Decision
- BMEA Strong Buy
- JMM
- Analyst Count
- BMEA 10
- JMM 0
- Target Price
- BMEA $22.30
- JMM N/A
- AVG Volume (30 Days)
- BMEA 2.3M
- JMM 16.1K
- Earning Date
- BMEA 07-30-2025
- JMM 01-01-0001
- Dividend Yield
- BMEA N/A
- JMM 5.44%
- EPS Growth
- BMEA N/A
- JMM N/A
- EPS
- BMEA N/A
- JMM N/A
- Revenue
- BMEA N/A
- JMM N/A
- Revenue This Year
- BMEA N/A
- JMM N/A
- Revenue Next Year
- BMEA N/A
- JMM N/A
- P/E Ratio
- BMEA N/A
- JMM N/A
- Revenue Growth
- BMEA N/A
- JMM N/A
- 52 Week Low
- BMEA $1.29
- JMM $5.29
- 52 Week High
- BMEA $13.07
- JMM $6.10
- Technical
- Relative Strength Index (RSI)
- BMEA 50.04
- JMM 65.15
- Support Level
- BMEA $1.58
- JMM $6.22
- Resistance Level
- BMEA $2.03
- JMM $6.41
- Average True Range (ATR)
- BMEA 0.15
- JMM 0.11
- MACD
- BMEA -0.00
- JMM 0.01
- Stochastic Oscillator
- BMEA 80.00
- JMM 100.00
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities including, but not limited to residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.